New drug duo tested in fight against recurrent ovarian cancer
NCT ID NCT06682572
Summary
This study is testing the safety and effectiveness of a two-drug combination (avutometinib and defactinib) for Japanese patients with recurrent low-grade ovarian cancer. The goal is to see if this treatment can shrink tumors and control the disease. It is for patients whose cancer has returned after prior chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Aichi Cancer Center Hospital
Nagoya, Aichi-ken, 464-8681, Japan
-
Jikei University Hospital
Minato, Tokyo, 105-0003, Japan
-
Kurume University Hospital
Kurume, Fukuoka, 830-0011, Japan
-
Mie University Hospital
Tsu, Mie-ken, 514-8507, Japan
-
Tohoku University Hospital
Sendai, Miyagi, 980-8574, Japan
Conditions
Explore the condition pages connected to this study.